Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.42 USD | -2.02% | -5.47% | -88.19% |
Apr. 03 | North American Morning Briefing : Powell Awaited -2- | DJ |
Apr. 02 | JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform | MT |
Valuation
Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|
Capitalization 1 | 184.9 | 609.4 | 72.19 | - | - |
Enterprise Value (EV) 1 | 85.63 | 609.4 | 20.39 | -10.11 | -26.61 |
P/E ratio | -3.42 x | -7.48 x | -0.94 x | -1.03 x | -3 x |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | 1.95 x |
EV / Revenue | - | - | - | - | -0.72 x |
EV / EBITDA | - | - | - | - | - |
EV / FCF | - | - | - | - | - |
FCF Yield | - | - | - | - | - |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 19,403 | 29,741 | 29,829 | - | - |
Reference price 2 | 9.530 | 20.49 | 2.420 | 2.420 | 2.420 |
Announcement Date | 3/29/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | 37.03 |
EBITDA | - | - | - | - | - | - |
EBIT 1 | - | -42.26 | -69.64 | -79.05 | -87.45 | -17.8 |
Operating Margin | - | - | - | - | - | -48.06% |
Earnings before Tax (EBT) | - | - | -64.73 | - | - | - |
Net income 1 | -28.06 | -42.78 | -64.73 | -81.13 | -94.13 | -53.07 |
Net margin | - | - | - | - | - | -143.29% |
EPS 2 | -25.02 | -2.790 | -2.740 | -2.565 | -2.355 | -0.8067 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/4/22 | 3/29/23 | 3/28/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -7.683 | -10.33 | -11.77 | -12.48 | -16.04 | -16.6 | -18.18 | -18.82 | -19.35 | -19.6 | -19.8 | -20.3 | -20 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) | - | - | - | - | - | - | - | -16.9 | - | - | - | - | - |
Net income 1 | -9.475 | -10.12 | -11.34 | -11.84 | -15.32 | -15.8 | -16.71 | -16.9 | -18.93 | -19.77 | -20.67 | -21.8 | -20 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -2.980 | -0.5300 | -0.5900 | -0.6100 | -0.7900 | -0.8100 | -0.6500 | -0.5700 | -0.6200 | -0.6300 | -0.6525 | -0.6650 | -0.6700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 5/10/22 | 8/11/22 | 11/9/22 | 3/29/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/28/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | 99.3 | - | 51.8 | 82.3 | 98.8 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/4/22 | 3/29/23 | 3/28/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-88.19% | 72.19M | |
+17.96% | 44.96B | |
+48.77% | 41.85B | |
+1.17% | 42.65B | |
-4.27% | 29.04B | |
+11.42% | 26.08B | |
-21.39% | 19.03B | |
+4.86% | 12.75B | |
+27.29% | 12.06B | |
-3.50% | 11.75B |
- Stock Market
- Equities
- ANTX Stock
- Financials AN2 Therapeutics, Inc.